# of Displayed Technologies: 10 / 30


Categories

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: Ezzell, Janel

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

Adoptive Transfer of Engineered Macrophages
TS-045881 — The Need Cell therapies have received recent approvals for immunomodulatory indications. Immuno-activating chimeric antigen receptor (CAR)–T cells have been developed for cancers, whereas immunosuppressive mesenchymal stromal cells (MSCs) have been approved for inflammatory bowel disease and …
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Hou, Xucheng; Zhang, Xinfu
  • Licensing Officer: Ezzell, Janel

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Ezzell, Janel

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Ezzell, Janel

Composition and method of lipid nanoparticles carrying oligonucleotides
TS-043629 — Novel lipid nanoparticles used for carrying antisense oligonucleotides with improved targeting for cancer treatment
Lung cancer is the leading cause of cancer related deaths in the US with approximately 150,000 deaths in 2017. Currently, mildly ineffective chemotherapeutics ripe with adverse side effects are the standard treatment. Antisense oligonucleotides (ASOs) are able to selectively modulate expression of
  • College: College of Pharmacy
  • Inventors: Lee, Robert; Cheng, Xinwei "Evan"
  • Licensing Officer: Ezzell, Janel

Self-assembled 3D RNA Cage Nanoparticles with Precise Shape and Size for Applications in Medical Sciences, Materials Sciences, Engineering and Nanotechnology
TS-039545 — Self-assembling, highly stable RNA cages amenable to custom functionalization and cargo delivery
One of the primary challenges in therapeutic development is cheap, efficient, and safe drug delivery to specific target tissues. To better target specific tissues, RNA nanotechnology has been progressively applied to generate predefined architectures via self-assembly of modular building blocks. N…
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel; Khisamutdinov, Emil; Li, Hui; Xu, Congcong
  • Licensing Officer: Ezzell, Janel

Method for Large scale production of RNA or RNA nanoparticles via the combination of rolling circle transcription and ribozyme processing.
TS-037876 — A new method to produce RNA and RNA nanoparticles by using rolling circle transcription to produce RNA on a large scale.
Since RNA interference was first described and utilized in 1998, the field has been expanding at an immense pace. Many types of therapeutics have been developed using synthetically constructed RNA interference nanotechnology, including work in the fields of cancer, immune therapy, and other human …
  • College: College of Pharmacy
  • Inventors: Guo, Peixuan; Jasinski, Daniel
  • Licensing Officer: Ezzell, Janel

Amino Esters and Uses Thereof
TS-037840 — Amino esters nanomaterials for gene therapy and drug delivery.
The Need The efficient delivery of mRNA is a key challenge for the application of mRNA therapeutics. Despite promising data from ongoing clinical trials for the treatment of cancer vaccines, the clinical use of mRNA requires the discovery and development of safer and more effective delivery systems…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Luo, Xiao; Zhang, Xinfu
  • Licensing Officer: Ezzell, Janel

Compound 13, an Mps1/TTK Kinase Inhibitor, for Triple Negative Breast Cancer Therapy
TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.
Breast cancer is a heterogeneous group of tumors, which can be subdivided based on histopathological features, genetic alterations, and gene-expression profiles. Approximately 50-60% of all breast cancer patients and two-thirds of postmenopausal breast cancer patients have estrogen receptor positi…
  • College: College of Pharmacy
  • Inventors: Brueggemeier, Robert; Fisk, Harold; Li, Chenglong; Li, Pui-Kai "Tom"; Sugimoto, Yasuro
  • Licensing Officer: Davis, Stewart

Show More Technologies

Loading icon